blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2411411

EP2411411 - NOVEL ANTI-ALPHA5BETA1 ANTIBODIES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  07.07.2017
Database last updated on 04.06.2024
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[N/P]
Former [2012/05]For all designated states
F.Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
Inventor(s)01 / LIANG, Wei-Ching
342 Menhaden Court
Foster City CA 94404 / US
02 / PLOWMAN, Gregory, D.
1386 Chestnut Street
San Carlos CA 94070 / US
03 / WU, Yan
1160 Blythe Street
Foster City CA 94404 / US
04 / YE, Weilan
119 Barkentine Street
Foster City CA 94404 / US
 [2016/35]
Former [2012/05]01 / LIANG, Wei-Ching
342 Menhaden Court
Foster City CA 94044 / US
02 / PLOWMAN, Gregory, D.
1386 Chestnut Street
San Carlos CA 94070 / US
03 / WU, Yan
1160 Blythe Street
Foster City CA 94404 / US
04 / YE, Weilan
119 Barkentine Street
Foster City CA 94404 / US
Representative(s)Brodbeck, Michel
F. Hoffmann-La Roche AG
Patent Department CLP
Grenzacherstrasse 124
4070 Basel / CH
[2016/35]
Former [2012/05]Brodbeck, Michel
F. Hoffmann-La Roche AG Patent Department CLP Grenzacherstrasse 124
4070 Basel / CH
Application number, filing date10710524.923.03.2010
[2016/35]
WO2010US28291
Priority number, dateUS20090163241P25.03.2009         Original published format: US 163241 P
[2012/05]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010111254
Date:30.09.2010
Language:EN
[2010/39]
Type: A1 Application with search report 
No.:EP2411411
Date:01.02.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 30.09.2010 takes the place of the publication of the European patent application.
[2012/05]
Type: B1 Patent specification 
No.:EP2411411
Date:31.08.2016
Language:EN
[2016/35]
Search report(s)International search report - published on:EP30.09.2010
ClassificationIPC:C07K16/28, C12N15/13, A61K39/395, A61P35/00
[2012/05]
CPC:
C07K16/2842 (EP,US); C07K16/28 (KR); A61K39/395 (KR);
A61K47/6835 (EP,US); A61P1/00 (EP); A61P13/12 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P27/00 (EP);
A61P27/02 (EP); A61P35/00 (EP); A61P37/00 (EP);
A61P37/02 (EP); A61P37/06 (EP); A61P9/00 (EP);
C07K16/22 (EP,US); C12N15/11 (KR); A61K2039/505 (EP,US);
A61K2039/507 (EP,US); C07K2317/24 (EP,US); C07K2317/31 (US);
C07K2317/56 (EP,US); C07K2317/565 (EP,US); C07K2317/92 (EP,US);
Y02A50/30 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/05]
Extension statesRS18.10.2011
TitleGerman:NEUE ANTI-ALPHA5BETA1-ANTIKÖRPER UND ANWENDUNGEN DAVON[2012/05]
English:NOVEL ANTI-ALPHA5BETA1 ANTIBODIES AND USES THEREOF[2012/05]
French:NOUVEAUX ANTICORPS ANTI-ALPHA5BETA1 ET LEURS UTILISATIONS[2012/09]
Former [2012/05]NOUVEAUX ANTICORPS ANTI- 5 1 ET LEURS UTILISATIONS
Entry into regional phase25.10.2011National basic fee paid 
25.10.2011Designation fee(s) paid 
25.10.2011Examination fee paid 
Examination procedure25.10.2011Examination requested  [2012/05]
15.05.2012Amendment by applicant (claims and/or description)
28.06.2013Despatch of a communication from the examining division (Time limit: M06)
31.01.2014Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
28.03.2014Reply to a communication from the examining division
04.05.2015Despatch of a communication from the examining division (Time limit: M04)
14.09.2015Reply to a communication from the examining division
06.04.2016Communication of intention to grant the patent
20.07.2016Fee for grant paid
20.07.2016Fee for publishing/printing paid
20.07.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  28.06.2013
Opposition(s)01.06.2017No opposition filed within time limit [2017/32]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
28.03.2014Request for further processing filed
28.03.2014Full payment received (date of receipt of payment)
Request granted
09.04.2014Decision despatched
Fees paidRenewal fee
07.03.2012Renewal fee patent year 03
08.03.2013Renewal fee patent year 04
10.03.2014Renewal fee patent year 05
06.03.2015Renewal fee patent year 06
08.03.2016Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.03.2010
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
TR31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
IS31.12.2016
PT02.01.2017
LU23.03.2017
MT23.03.2017
[2020/33]
Former [2020/15]HU23.03.2010
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
TR31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
LU23.03.2017
MT23.03.2017
Former [2019/51]HU23.03.2010
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
MK31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
LU23.03.2017
MT23.03.2017
Former [2019/46]HU23.03.2010
AT31.08.2016
BE31.08.2016
CY31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
LU23.03.2017
MT23.03.2017
Former [2019/31]HU23.03.2010
AT31.08.2016
BE31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
LU23.03.2017
MT23.03.2017
Former [2018/43]AT31.08.2016
BE31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
LU23.03.2017
MT23.03.2017
Former [2018/10]AT31.08.2016
BE31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
LU23.03.2017
Former [2018/01]AT31.08.2016
BE31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
MC31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/37]AT31.08.2016
BE31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
PL31.08.2016
RO31.08.2016
SI31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/32]AT31.08.2016
BE31.08.2016
CZ31.08.2016
EE31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
IT31.08.2016
LT31.08.2016
LV31.08.2016
PL31.08.2016
RO31.08.2016
SK31.08.2016
SM31.08.2016
BG30.11.2016
NO30.11.2016
GR01.12.2016
PT02.01.2017
Former [2017/13]AT31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
LT31.08.2016
LV31.08.2016
NO30.11.2016
GR01.12.2016
Former [2017/11]AT31.08.2016
ES31.08.2016
FI31.08.2016
HR31.08.2016
LT31.08.2016
NO30.11.2016
GR01.12.2016
Former [2017/10]FI31.08.2016
HR31.08.2016
LT31.08.2016
NO30.11.2016
Former [2017/09]FI31.08.2016
LT31.08.2016
NO30.11.2016
Former [2017/07]LT31.08.2016
Cited inInternational search[Y]WO2004056308  (PROTEIN DESIGN LABS INC [US], et al) [Y] 1-36 * the whole document *;
 [Y]WO2004089988  (PROTEIN DESIGN LABS INC [US], et al) [Y] 1-36 * the whole document *;
 [Y]WO2005092073  (PROTEIN DESIGN LABS INC [US], et al) [Y] 1-36 * the whole document *;
 [Y]WO2007134876  (BAYER SCHERING PHARMA AG [DE], et al) [Y] 1-36 * the whole document *;
 [Y]WO2008060645  (GENENTECH INC [US], et al) [Y] 1-36 * the whole document *;
 [YP]WO2009042746  (GENENTECH INC [US], et al) [YP] 1-36 * the whole document *;
 [YP]WO2009100110  (MEDAREX INC [US], et al) [YP] 1-36* the whole document *;
 [A]  - HOLT L J ET AL, "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB LNKD- DOI:10.1016/J.TIBTECH.2003.08.007, (20031101), vol. 21, no. 11, ISSN 0167-7799, pages 484 - 490, XP004467495 [A] 1-36 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.tibtech.2003.08.007
 [A]  - DAVIES J ET AL, "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL LNKD- DOI:10.1016/S1380-2933(96)00045-0, (19960901), vol. 2, no. 3, ISSN 1380-2933, pages 169 - 179, XP004070292 [A] 1-36 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1380-2933(96)00045-0
 [A]  - MOULD A P ET AL, "Defining the topology of integrin alpha5beta1-fibronectin interactions using inhibitory anti-alpha5 and anti-beta1 monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the alpha5 subunit", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.272.28.17283, (19970711), vol. 272, no. 28, ISSN 0021-9258, pages 17283 - 17292, XP002485038 [A] 1-36 * the whole document *

DOI:   http://dx.doi.org/10.1074/jbc.272.28.17283
 [A]  - BURROWS L ET AL, "Fine mapping of inhibitory anti-alpha5 monoclonal antibody epitopes that differentially affect integrin-ligand binding", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB LNKD- DOI:10.1042/0264-6021:3440527, (19991201), vol. 344, no. Pt 2, ISSN 0264-6021, pages 527 - 533, XP002485037 [A] 1-36 * the whole document *

DOI:   http://dx.doi.org/10.1042/0264-6021:3440527
 [A]  - ORECCHIA ANGELA ET AL, "Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha5beta1 integrin", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB LNKD- DOI:10.1242/JCS.00673, (20030901), vol. 116, no. 17, ISSN 0021-9533, pages 3479 - 3489, XP002468572 [A] 1-36 * the whole document *

DOI:   http://dx.doi.org/10.1242/jcs.00673
 [A]  - RAMAKRISHNAN V ET AL, "Preclinical evaluation of an anti-ÄalphaÜ5ÄbetaÜ1 integrin antibody as a novel anti-angiogenic agent", JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, RAPID SCIENCE PUBLISHERS, LONDON, GB, (20060504), vol. 5, no. 4, ISSN 1359-4117, pages 273 - 286, XP008081487 [A] 1-36 * the whole document *
 [A]  - ECONOMOPOULOU MATINA ET AL, "Inhibition of pathologic retinal neovascularization by alpha-defensins", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US LNKD- DOI:10.1182/BLOOD-2005-03-0889, (20051201), vol. 106, no. 12, ISSN 0006-4971, pages 3831 - 3838, XP002495156 [A] 1-36 * the whole document *

DOI:   http://dx.doi.org/10.1182/blood-2005-03-0889
Examination   - WARK K L ET AL, "Latest technologies for the enhancement of antibody affinity", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 58, no. 5-6, doi:10.1016/J.ADDR.2006.01.025, ISSN 0169-409X, (20060807), pages 657 - 670, (20060807), XP024892147

DOI:   http://dx.doi.org/10.1016/j.addr.2006.01.025
    - CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", THE JOURNAL OF IMMUNOLOGY, NATURE PUB. GROUP, (20060407), vol. 6, doi:10.1038/NRI1837, ISSN 1474-1733, pages 343 - 357, XP007901440

DOI:   http://dx.doi.org/10.1038/nri1837
by applicantUS3773919
 US4179337
 US4301144
 US4485045
 US4496689
 US4544545
 US4640835
 US4670417
 US4675187
 US4676980
 US4791192
 US4816567
 US4933294
 EP0404097
 US4994560
 WO9105264
 US5013556
 US5208020
 WO9308829
 WO9311161
 US5274119
 WO9411026
 US5342604
 WO9429351
 US5401638
 US5416064
 US5428130
 US5428139
 US5435990
 US5489425
 US5500362
 US5505931
 EP0425235
 WO9704801
 US5624821
 US5635483
 US5641870
 US5648260
 US5652361
 WO9730087
 US5696239
 US5712374
 US5714586
 US5714631
 US5731168
 US5739116
 US5750373
 US5756065
 US5767285
 US5770429
 US5770701
 US5770710
 US5773001
 US5780588
 US5808003
 US5821337
 WO9845331
 WO9845479
 WO9856418
 WO9858964
 US5877296
 WO9922764
 WO9951642
 US6075181
 WO0042072
 WO0061739
 US6150584
 US6194551
 WO0129246
 US6235764
 WO0231140
 US2002164328
 WO03011878
 US6534524
 US2003115614
 US6602684
 US2003157108
 US6630579
 US2003190317
 WO03085119
 WO03084570
 WO03085107
 US2004093621
 US6737056
 US2004110704
 US2004110282
 US2004109865
 US2004132140
 WO2004056312
 WO2004113304
 US2005014934
 WO2005012359
 US2005079574
 WO2005035586
 WO2005035778
 US6884879
 WO2005044853
 US2005119455
 US2005123546
 WO2005053742
 WO2005100402
 US2005260186
 US2005266000
 US6982321
 US2006025576
 WO2006029879
 US7041870
 US2006104968
 US7087409
 US7189826
 US2007061900
 US2007117126
 US2007160598
 US2007237764
 US2007292936
 US7332581
 US2008069820
 US7371826
 WO2008077546
 US2009002360
 US7498298
 US7521541
 US7527791
 WO2009089004
    - LEUNG ET AL., SCIENCE, (1989), vol. 246, page 1306
    - HOUCK ET AL., MOL. ENDOCRIN., (1991), vol. 5, page 1806
    - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599
    - KLAGSBRUN; D'AMORE, ANNU. REV. PHYSIOL., (1991), vol. 53, pages 217 - 239
    - DETMAR, ONCOGENE, (2003), vol. 22, pages 3172 - 3179
    - FERRARA; ALITALO, NATURE MEDICINE, (1999), vol. 5, no. 12, pages 1359 - 1364
    - TONINI ET AL., ONCOGENE, (2003), vol. 22, pages 6549 - 6556
    - SATO, INT. J. CLIN. ONCOL., (2003), vol. 8, pages 200 - 206
    - KLAGSBRUN; D'AMORE, ANNU. REV. PHYSIOL, (1991), vol. 53, pages 217 - 239
    - STREIT; DETMAR, ONCOGENE, (2003), vol. 22, pages 3172 - 3179
    - CHEN ET AL., J. MOL BIOL, (1999), vol. 293, pages 865 - 881
    - CHEN, Y. ET AL., J. MOL BIOL, (1999), vol. 293, pages 865 - 881
    - "Cell cycle regulation, oncogenes, and antineoplastic drugs", MURAKAMI ET AL., The Molecular Basis of Cancer, WB SAUNDERS, (1995), page 13
    - AGNCW, CHCM INTL. ED. ENGL., (1994), vol. 33, pages 183 - 186
    - WILMAN, "Prodrugs in Cancer Chemotherapy", BIOCHEMICAL SOCIETY TRANSACTIONS, (1986), vol. 14, pages 375 - 382
    - "Prodrugs: A Chemical Approach to Targeted Drug Delivery", STELLA ET AL., Directed Drug Delivery, HUMANA PRESS, (1985), pages 247 - 267
    - BASIC AND CLINICAL IMMUNOLOGY, APPLETON & LANGE, (1994), page 71
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - KOHLER ET AL., NATURE, (1975), vol. 256, page 495
    - CLACKSON, NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
    - MORRISON ET AL., PNAS USA, (1984), vol. 81, pages 6851 - 6855
    - MARKS ET AL., BIOLTECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - BARBAS ET AL., PNAS USA, (1994), vol. 91, pages 3809 - 3813
    - SCHIER ET AL., GENE, (1995), vol. 169, pages 147 - 155
    - YELTON ET AL., J. IMMUNOL., (1995), vol. 155, pages 1994 - 2004
    - JACKSON ET AL., J. IMMUNOL., (1995), vol. 154, no. 7, pages 3310 - 3319
    - HAWKINS ET AL., J. MOL. BIOL., (1992), vol. 226, pages 889 - 896
    - ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062
    - Pluckthun in The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - HOLLINGER ET AL., PNAS USA, (1993), vol. 90, pages 6444 - 6448
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
    - DACRON, ANNU. REV. IMMUNOL., (1997), vol. 15, pages 203 - 234
    - RAVETCH; KINET, ANNU. REV. IMMUNOL, (1991), vol. 9, pages 457 - 492
    - CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34
    - DE HAAS ET AL., J. LAB. CLIN. MED., (1995), vol. 126, pages 330 - 341
    - GUYER ET AL., J. IMMUNOL., (1976), vol. 117, page 587
    - KIM ET AL., J. IMMUNOL, (1994), vol. 24, page 249
    - GHETIE; WARD, ANNU. REV. IMMUNOL., (2000), vol. 18, pages 739 - 766
    - SHIELDS ET AL., J. BIOL. CHEM., (2001), vol. 9, no. 2, pages 6591 - 6604
    - BURTON, MOLEC. IMMUNOL., (1985), vol. 22, pages 161 - 206
    - RAVETCH; KINET, ANNU. REV. LMMUNOL, (1991), vol. 9, pages 457 - 92
    - CLYNES ET AL., PNAS (USA), (1998), vol. 95, pages 652 - 656
    - GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, (1996), vol. 202, page 163
    - IDUSOGIE ET AL., J. IMMUNOL., (2000), vol. 164, pages 4178 - 4184
    - WELLS; LOWMAN, CURR. OPIN. STRUCT. BIOL., (1992), vol. 3, pages 355 - 362
    - LOWMAN; WELLS, METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, (1991), vol. 3, pages 205 - 0216
    - T.E. CREIGHTON, Proteins: Structure and Molecular Properties, W.H. FREEMAN & CO., (1983), pages 79 - 86
    - SCHWARZE ET AL., SCIENCE, (1999), vol. 285, pages 1569 - 72
    - FIELD ET AL., MOL. CELL. BIOL., (1988), vol. 8, pages 2159 - 2165
    - EVAN ET AL., MOLECULAR AND CELLULAR BIOLOGY, (1985), vol. 5, pages 3610 - 3616
    - PABORSKY ET AL., PROTEIN ENGINEERING, (1990), vol. 3, no. 6, pages 547 - 553
    - HOPP ET AL., BIOTECHNOLOGY, (1988), vol. 6, pages 1204 - 1210
    - MARTIN ET AL., SCIENCE, (1992), vol. 255, pages 192 - 194
    - SKINNER ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 15163 - 15166
    - LUTZ-FREYERMUTH ET AL., PNAS USA, (1990), vol. 87, pages 6393 - 6397
    - LAZARUS ET AL., "Definitions and guidelines for assessment of wounds and evaluation of healing", ARCH. DERMATOL., (1994), vol. 130, pages 489 - 93
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495
    - GODING, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, ACADEMIC PRESS, (1986), pages 59 - 103
    - KOZBOR, J. Immunol., (1984), vol. 133, page 3001
    - BRODEUR ET AL., MONOCLONAL ANTIBODY PRODUCTION TECHNIQUES AND APPLICATIONS, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - MUNSON; POLLARD, ANAL. BIOCHEM., (1980), vol. 107, page 220
    - VAN DIJK; VAN DE WINKEL, CURR. OPIN. PHARMACOL., (2001), vol. 5, pages 368 - 74
    - LONBERG, CURR. OPIN. IMMUNOL., (2008), vol. 20, pages 450 - 459
    - LONBERG, NAT. BIOTECH., (2005), vol. 23, pages 1117 - 1125
    - KOZBORJ., IMMUNOL., (1984), vol. 133, page 3001
    - BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, page 86
    - LI ET AL., PNAS, USA, (2006), vol. 103, pages 3557 - 3562
    - NI, XIANDAI MIANYIXUE, (2006), vol. 26, no. 4, pages 265 - 268
    - VOLLMERS; BRANDLEIN, HISTOLOGY AND HISTOPATHOLOGY, (2005), vol. 20, no. 3, pages 927 - 937
    - VOLLMERS; BRANDLEIN, METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, (2005), vol. 27, no. 3, pages 185 - 191
    - HOOGENBOOM ET AL., Methods in Molecular Biology, HUMAN PRESS, (2001), vol. 178, pages 1 - 37
    - THE MCCAFFERTY ET AL., NATURE, vol. 348, pages 552 - 554
    - MARKS ET AL., J. MOL. BIOL., (1992), vol. 222, pages 581 - 597
    - MARKS; BRADBURY, Methods in Molecular Biology, HUMAN PRESS, (2003), vol. 248, pages 161 - 175
    - SIDHU ET AL., J. MOL. BIOL., (2004), vol. 338, no. 2, pages 299 - 310
    - LEE ET AL., J MOL. BIOL., (2004), vol. 340, no. 5, pages 1073 - 1093
    - FELLOUSE, PNAS USA, (2004), vol. 101, no. 34, pages 12467 - 12472
    - LEE ET AL., J. IMMUNOL. METHODS, (2004), vol. 284, no. 1-2, pages 119 - 132
    - WINTER ET AL., ANN. REV. IMMUNOL., (1994), vol. 12, pages 433 - 455
    - GRIFFITHS ET AL., EMBO.L, (1993), vol. 12, pages 725 - 734
    - HOOGENBOOM; WINTER, J. MOL. RIOL., (1992), vol. 227, pages 381 - 388
    - ALMAGRO; FRANSSON, FRONT. BIOSCI., (2008), vol. 13, pages 1619 - 1633
    - QUEEN ET AL., PNAS USA, (1989), vol. 86, pages 10029 - 10033
    - KASHMIRI ET AL., METHODS, (2005), vol. 36, pages 25 - 34
    - PADLAN, MOL. IMMUNOL., (1991), vol. 28, pages 489 - 498
    - DALL'ACQUA ET AL., METHODS, (2005), vol. 36, pages 43 - 60
    - OSBOURN ET AL., METHODS, (2005), vol. 36, pages 61 - 68
    - KLIMKA ET AL., BR. J. CANCER, (2000), vol. 83, pages 252 - 260
    - SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296
    - CARTER ET AL., PNAS USA, (1992), vol. 89, page 4285
    - PRESTA ET AL., J. IMMUNOL., (1993), vol. 151, page 2623
    - BACA ET AL., J. BIOL. CHEM., (1997), vol. 272, pages 10678 - 10684
    - ROSOK ET AL., J. BIOL. CHEM., (1996), vol. 271, pages 22611 - 22618
    - MILSTEIN; CUELLO, NATURE, (1983), vol. 305, page 537
    - TRAUNECKER ET AL., EMBOJ., (1991), vol. 10, page 3655
    - BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81
    - KOSTELNY ET AL., J. IMMUNOL., (1992), vol. 148, no. 5, pages 1547 - 1553
    - GRUBER ET AL., J. IMMUNOL., (1994), vol. 152, page 5368
    - TUTT ET AL., J. IMMUNOL., (1991), vol. 147, page 60
    - CHOWDHURY, METHODS MOL. BIOL., (2008), vol. 207, pages 179 - 196
    - CUNNINGHAM; WELLS, SCIENCE, (1989), vol. 244, pages 1081 - 1085
    - WRIGHT ET AL., TIBTECH, (1997), vol. 15, pages 26 - 32
    - OKAZAKI ET AL., J. MOL. BIOL., (2004), vol. 336, pages 1239 - 1249
    - YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., (2004), vol. 87, page 614
    - RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., (1986), vol. 249, pages 533 - 545
    - KANDA, Y. ET AL., BIOTECHNOL. BIOENG., (2006), vol. 94, no. 4, pages 680 - 688
    - RAVETCH; KINET, ANNU. REV. IMMUNOL., (1991), vol. 9, pages 457 - 492
    - HELLSTROM, 1. ET AL., PNAS USA, (1986), vol. 83, pages 7059 - 7063
    - HELLSTROM, I ET AL., PNAS USA, (1985), vol. 82, pages 1499 - 1502
    - BRUGGEMANN, M. ET AL., J. EXP. MED., (1987), vol. 166, pages 1351 - 1361
    - CLYNES ET AL., PNAS USA, (1998), vol. 95, pages 652 - 656
    - CRAGG, M.S. ET AL., BLOOD, (2003), vol. 101, pages 1045 - 1052
    - CRAGG, M.S.; M.J. GLENNIE, BLOOD, (2004), vol. 103, pages 2738 - 2743
    - PETKOVA, S.B. ET AL., INT'L. IMMUNOL., (2006), vol. 18, no. 12, pages 1759 - 1769
    - SHIELDS, RL ET AL., JBC, (2001), vol. 276, no. 6, pages 6591 - 6604
    - PRESTA, L.G., BIOCHEMICAL SOCIETY TRANSACTIONS, (2002), vol. 30, no. 4, pages 487 - 490
    - KIM ET AL., J. IMMUNOL., (1994), vol. 24, page 249
    - DUNCAN; WINTER, NATURE, (1988), vol. 322, pages 738 - 40
    - CARON ET AL., J. EXP. MED., (1992), vol. 176, pages 1191 - 1195
    - SHOPES, J. IMMUNOL., (1992), vol. 148, pages 2918 - 2922
    - WOLFF ET AL., CANCER RESEARCH, (1993), vol. 53, pages 2560 - 2565
    - STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, (1989), vol. 3, pages 219 - 230
    - KAM ET AL., PROC. NATL. ACAD. SCI. USA, (2005), vol. 102, pages 11600 - 11605
    - HINMAN ET AL., CANCER RES., (1993), vol. 53, pages 3336 - 3342
    - LODE ET AL., CANCER RES., (1998), vol. 58, pages 2925 - 2928
    - KRATZ ET AL., CURRENT MED. CHEM., (2006), vol. 13, pages 477 - 523
    - JEFFREY ET AL., BIOORGANIC & MED. CHEM. LETTERS, (2006), vol. 16, pages 358 - 362
    - TORGOV ET AL., BIOCONJ. CHEM., (2005), vol. 16, pages 717 - 721
    - NAGY ET AL., PROC. NATL. ACAD. SCI. USA, (2000), vol. 97, pages 829 - 834
    - DUBOWCHIK ET AL., BIOORG. & MED. CHEM. LETTERS, (2002), vol. 12, pages 1529 - 1532
    - KING ET AL., J. MED. CHEM., (2002), vol. 45, pages 4336 - 4343
    - VITETTA ET AL., SCIENCE, (1987), vol. 238, page 1098
    - CHARI ET AL., CANCER RES., (1992), vol. 52, pages 127 - 131
    - EPSTEIN ET AL., PNAS USA, (1985), vol. 82, page 3688
    - HWANG ET AL., PNAS USA, (1980), vol. 77, page 4030
    - MARTIN ET AL., J. BIOL. CHEM., (1982), vol. 257, pages 286 - 288
    - GABIZON ET AL., J. NATIONAL CANCER INST., (1989), vol. 81, no. 19, page 1484
    - MARASCO ET AL., PNAS USA, (1993), vol. 90, pages 7889 - 7893
    - JALKANEN ET AL., J. CELL. BIOL., (1985), vol. 101, pages 976 - 985
    - JALKANEN ET AL., J CELL. BIOL., (1987), vol. 105, pages 3087 - 3096
    - SIAS ET AL., J. IMMUNOL. METHODS, (1990), vol. 132, pages 73 - 80
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.